Testing DNA methylation profiling on small brain tumor biopsy samples
Original title: Methylation profiling and alternative classification approaches in a glioma-enriched FFPE stereotaxic biopsy cohort.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked back at tissue already taken from patients to check how well a lab test works, and it is not a treatment.
The short version
Researchers checked how well a lab test that reads DNA patterns can identify brain tumors when only a tiny piece of tissue is available.
What was studied. Researchers looked at stored tumor tissue samples from 237 patients. The samples came from stereotaxic biopsies, which take only a very small piece of tissue. The team ran DNA methylation testing on each sample using three different classifier tools.
What they found. The test placed 90.5% of samples (232) into a DNA methylation class. Signs of chromosome changes were found in 96.9% of cases. How well the test worked depended on what the tissue looked like under the microscope first. It classified 96.2% of malignant diffuse gliomas, 91.5% of diffuse gliomas, but only 60% of circumscribed gliomas.
What this means, and what it doesn't
What it could mean: If you need a biopsy that takes only a small piece of tissue, this kind of DNA testing can often still give doctors detailed information about the tumor type and grade. That can help guide decisions about care.
What it doesn't mean: This is not a treatment. It is a study of a diagnostic lab method, not a new therapy, and it is not a cure or a promise of one. The researchers used tissue that had already been collected, so nobody was treated differently because of this work. The method did not work for every tumor. Tumors deep in the middle of the brain and some lower grade tumors were harder to identify. Whether this testing is available to you depends on your hospital and your lab.
Source: PubMed, July 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.